OptimizeRx Corporation
Rank #109Op. LeverageOPRX · Nasdaq · Healthcare
OptimizeRx Corporation (OPRX) — Rank #109 by gross profitability (GP/assets 0.45) · ROE 3.9% · Piotroski F-Score 8 / 9.
As-of 2026-09-15 · CIK 0001448431 · all metrics point-in-time as of the filing date.
About
OptimizeRx Corporation operates as a digital healthcare technology company.
Show moreShow less
It offers Dynamic Audience Activation Platform, which generates dynamic audiences with predictive analytics through machine learning methods; Micro-Neighborhood Targeting, which creates consumer audiences using a privacy-first process; Profiler, which provides insights into its customers' target consumers; banner messages, including brand messaging, therapeutic support messaging, affordability messaging, limited distribution drug information, and patient support program messaging through healthcare professionals; and media execution solutions, which deliver messages through consumer omnichannel network, including through programmatic display, programmatic connected television/over-the-top, programmatic social media, addressable television, digital out-of-home, programmatic audio, and email/direct mail. The company also offers pharmacy alerts, which flag pharmacies that have prescription medications in stock; and financial messaging solutions, which provide prescribers visibility to branded copay offers for patients directly within electronic health record systems and ePrescribing platforms.
The company was founded in 2006 and is headquartered in Waltham, Massachusetts.
- Industry
- Health Information Services
- Sector
- Healthcare
- State
- NV
- Filer Category
- Non-accelerated filerSmaller reporting company
- Fiscal Year End
- December 31
- Website
- optimizerx.com
Price History
Company Snapshot
P/E and reverse DCF are the primary valuation lenses at this stage.
Market Cap
$143.25M
P/E (annual)
28.2
P/S (annual)
1.3
P/B
1.1
P/OCF (annual)
7.7
Shareholder Yield
-3.9%
Employees
132
Industry
Health Information Services
Exchange
Nasdaq
Signal Flags
Quality Profile
Profitability
1/1 passSafety
1/1 passCash Flow
3/3 passGrowth
1/2 passTerry Smith quality gate
Passes 2/5 Terry Smith thresholds1 of 5 threshold not computable from filed data.
What Growth Is Priced In
Implied revenue growth (10Y)
-5.5%
The annual FCF growth rate today's price requires over a 10-year horizon (discount rate 10%, terminal growth 2.5%).
Dilution drag: 3.9% — per-share value needs a total required return of -1.7% once share-count change is priced in.
vs. own 6-year median revenue growth: 23.8%
within its own historyCost-of-equity sensitivity (implied growth at different discount rates)
r = 8%
-9.0%
r = 10% (base)
-5.5%
r = 12%
-2.5%
Net debt / market cap: -3.5%
Note: current FCF margin is 1.6σ above its historical mean — implied growth may understate valuation risk if the margin reverts.
Valuation History
Current multiple vs historical range at each filing date. Band spans 25th-75th percentile.
P / E
Price / diluted EPS
P / S
Price / revenue per share
P / B
Price / book value per share
P / GP
Price / gross profit per share
P / FCF
Price / free cash flow per share
Earnings bubble check
Current margins may be above sustainable levels — a P/E based on peak earnings can overstate cheapness.
Operating margin expansion and free cash flow are the primary reads at this stage.
Profitability
Gross profitability (GP / assets)
0.45
Primary signal (Novy-Marx).
5th of 9 SIC 7389 peers
Return on equity
3.9%
Gross margin
67.3%
4th of 9 SIC 7389 peers
Revenue growth (YoY)
18.8%
Gross margin improving
Margin trend vs prior year.
Operating Leverage
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Revenue vs COGS | ||||
| Revenue vs OpEx | ||||
| Op. Income vs Revenue |
Growth
Revenue CAGR (3Y)
20.6%
Revenue CAGR (5Y)
20.4%
Earnings CAGR (3Y)
—
FCF CAGR (3Y)
20.8%
Anti-fragile safety
Balance-sheet safety
Composite anti-fragile check.
Debt / equity
0.25
1st of 7 SIC 7389 peers (best = lowest)
Current ratio
5.58×
1st of 9 SIC 7389 peers
Quick ratio
5.03×
Net cash
$5.09M
Cash & equivalents minus total debt.
Recession resistance
Revenue through recessions
Worst single-year YoY revenue decline, 16 years of history
Cash-flow health
Free cash flow
$18.66M
Operating cash flow minus capex.
Positive free cash flow
FCF / net income
2.64
Cash-backing of earnings.
FCF/NI divergence
Unfavorable divergence (yellow flag).
Accruals healthy
Cash-backed earnings.
SBC / revenue
6.4%
Stock-based comp intensity.
Piotroski F-Score
F-Score
8 / 9
Fundamental-strength score (0-9).